EP3515465

REGENERON PHARMACEUTICALS, INC.
Application Number
EP17777145A
Filing Date
Sep 21, 2017
Status
Granted And Under Opposition
Jan 5, 2024
Grant Date
Feb 7, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3515465B1 was granted on Feb 7, 2024 by Regeneron Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

The table below shows 7 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLER LLPNov 7, 2024ADMISSIBLE
DORRIES, HANS ULRICHNov 7, 2024ADMISSIBLE
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBNov 7, 2024ADMISSIBLE
BOULT WADE TENNANT LLPNov 6, 2024ADMISSIBLE
RUMI, LUIGINov 6, 2024ADMISSIBLE
SECERNA LLPNov 6, 2024ADMISSIBLE
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBNov 5, 2024ADMISSIBLE

The table below shows the patents of Regeneron Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3110848Methods For Treating Skin Infection By Administering An Il-4R AntagonistFeb 14, 20245
EP3973987Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistJan 10, 20246
EP4011915Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistNov 15, 20236

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.